Cue Biopharma Temettü

Temettü kriter kontrolleri 0/6

Cue Biopharma şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-16.4%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-16.4%
Gelecekteki Temettü Verimi	n/a
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü güncellemeleri

Güncelleme yok

Recent updates

Cue Biopharma shares rise ~10% on FDA fast track nod for head and neck cancer drug

Oct 04

Despite Lacking Profits Cue Biopharma (NASDAQ:CUE) Seems To Be On Top Of Its Debt

Sep 23

News Flash: 4 Analysts Think Cue Biopharma, Inc. (NASDAQ:CUE) Earnings Are Under Threat

Aug 26

Analysts Just Shipped A Huge Upgrade To Their Cue Biopharma, Inc. (NASDAQ:CUE) Estimates

Aug 10

Analysts Have Just Cut Their Cue Biopharma, Inc. (NASDAQ:CUE) Revenue Estimates By 23%

May 18

Cue Biopharma (NASDAQ:CUE) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

May 12

Cue Biopharma: A First Assessment

May 11

Earnings Beat: Cue Biopharma, Inc. (NASDAQ:CUE) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Mar 19

Cue Biopharma: Too Long To Arrive At Topline Trial Data

Feb 23

We Think Cue Biopharma (NASDAQ:CUE) Can Afford To Drive Business Growth

Nov 04

Cue Biopharma doses first patient in trial for CUE-101 in head and neck cancer

Jun 10

Companies Like Cue Biopharma (NASDAQ:CUE) Are In A Position To Invest In Growth

Jun 07

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: CUE şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: CUE şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Cue Biopharma Piyasaya Karşı Temettü Getirisi

CUE temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (CUE)	n/a
Pazarın Alt %25'i (US)	1.4%
Pazarın En İyi %25'i (US)	4.5%
Sektör Ortalaması (Biotechs)	2.2%
Analist tahmini (CUE) (3 yıla kadar)	n/a

Önemli Temettü: CUE şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, CUE şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: CUE şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: CUE herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Cue Biopharma Temettü

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü güncellemeleri

Recent updates

Cue Biopharma, Inc. has completed a Follow-on Equity Offering in the amount of $12 million.

New major risk - Share price stability

Cue Biopharma, Inc. has completed a Follow-on Equity Offering in the amount of $12 million.

Cue Biopharma, Inc. Appoints Lucinda Warren as Chief Business Officer

Consensus estimates of losses per share improve by 20%

Cue Biopharma Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement

Cue Biopharma Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 15% to US$8.00

Cue Biopharma, Inc.(NasdaqCM:CUE) dropped from Russell Small Cap Completeness Index

Cue Biopharma, Inc. Appoints Michael J. Fox to the Board of Directors and the Compensation Committee

Consensus revenue estimates increase by 17%

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Cue Biopharma, Inc., Annual General Meeting, Jun 05, 2024

Here's Why Cue Biopharma (NASDAQ:CUE) Can Manage Its Debt Despite Losing Money

New major risk - Revenue and earnings growth

Consensus EPS estimates fall by 20%

Full year 2023 earnings: EPS and revenues exceed analyst expectations

New major risk - Revenue and earnings growth

New minor risk - Market cap size

Does Cue Biopharma (NASDAQ:CUE) Have A Healthy Balance Sheet?

Consensus revenue estimates decrease by 25%

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Cue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Cancer and Cue-102 in Wilms' Tumor 1 Positive Cancers at SITC 2023

New minor risk - Share price stability

Cue Biopharma Announces Completion of Patient Enrollment in Phase 1b Study of CUE-101 in Combination with KEYTRUDA®?

Cue Biopharma, Inc. Announces Resignation of Aaron Fletcher as Member of the Board of Directors, Effective October 9, 2023

Is Cue Biopharma (NASDAQ:CUE) Using Too Much Debt?

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Cue Biopharma, Inc. Presents Positive Data Update from Ongoing Phase 1 Trials of Cue-101 for Recurrent/Metastatichpv+ Head and Neck Squamous Cell Carcinoma At the 2023 American Society of Clinical Oncology Annual Meeting

Consensus revenue estimates decrease by 91%, EPS upgraded

Cue Biopharma, Inc. has completed a Follow-on Equity Offering in the amount of $17.6 million.

First quarter 2023 earnings: EPS in line with expectations, revenues disappoint

Consensus revenue estimates fall by 24%

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Cue Biopharma, Inc. Announces the Appointment of Rafi Ahmed to its Scientific Advisory Board

Cue Biopharma, Inc. Announces Executive Changes

Consensus forecasts updated

Cue Biopharma, Inc. announced that it expects to receive $29.999992 million in funding

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Cue Biopharma, Inc. Presents New Positive Data from Ongoing Phase 1 Trial of Cue-101 in Combination with Keytruda for Recurrent/Metastatic Hpv+ Head and Neck Cancer At the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting

Cue Biopharma Grants FDA Fast Track Designation for CUE-101 for the Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Cue Biopharma shares rise ~10% on FDA fast track nod for head and neck cancer drug

Despite Lacking Profits Cue Biopharma (NASDAQ:CUE) Seems To Be On Top Of Its Debt

News Flash: 4 Analysts Think Cue Biopharma, Inc. (NASDAQ:CUE) Earnings Are Under Threat

Consensus revenue estimates fall by 50%

Cue Biopharma Doses First Patient in Phase 1 Study of CUE-102 for Wilms’ Tumor 1 (WT1) - Expressing Cancers

Consensus revenue estimates increase by 54%

Analysts Just Shipped A Huge Upgrade To Their Cue Biopharma, Inc. (NASDAQ:CUE) Estimates

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Cue Biopharma, Inc. Announces Resignation of Cameron Gray as Member of the Board of Directors and All Committees

Insider recently bought US$105k worth of stock

Analysts Have Just Cut Their Cue Biopharma, Inc. (NASDAQ:CUE) Revenue Estimates By 23%

Consensus revenue estimates fall by 23%

Cue Biopharma (NASDAQ:CUE) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

U.S. Food and Drug Administration Accepts Cue Biopharma, Inc Investigational New Drug Application

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Cue Biopharma: A First Assessment

Cue Biopharma, Inc., Annual General Meeting, Jun 09, 2022

Price target decreased to US$24.83

CEO & Director exercised options and sold US$157k worth of stock

Consensus forecasts updated

Price target decreased to US$26.29

Earnings Beat: Cue Biopharma, Inc. (NASDAQ:CUE) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Cue Biopharma: Too Long To Arrive At Topline Trial Data

President & Chief Scientific Officer exercised options and sold US$173k worth of stock

Third quarter 2021 earnings released: US$0.41 loss per share (vs US$0.34 loss in 3Q 2020)

We Think Cue Biopharma (NASDAQ:CUE) Can Afford To Drive Business Growth

CEO & Director exercised options and sold US$462k worth of stock

Cue Biopharma, Inc. Announces Publication in Nature Journal, Scientific Reports, of Immunotherapeutic Platforms Immuno-STAT and Neo-STAT

President & Chief Scientific Officer exercised options and sold US$176k worth of stock

CEO & Director recently bought US$50k worth of stock

Cue Biopharma, Inc Grants U.S. Patents on Lead Clinical Program Novel Drug Product Candidate CUE-101

Consensus revenue estimates increase to US$10.4m